Bangkok Lab and Cosmetic PCL
SET:BLC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
China Tungsten and Hightech Materials Co Ltd
SZSE:000657
|
CN |
|
China Suntien Green Energy Corp Ltd
SSE:600956
|
CN |
|
V2 Retail Ltd
NSE:V2RETAIL
|
IN |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (8.3), the stock would be worth ฿3.88 (0% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 8.3 | ฿3.88 |
0%
|
| 3-Year Average | 8.3 | ฿3.88 |
+0%
|
| 5-Year Average | 8.3 | ฿3.88 |
+0%
|
| Industry Average | 8.3 | ฿3.86 |
0%
|
| Country Average | 8.6 | ฿4.03 |
+4%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| TH |
B
|
Bangkok Lab and Cosmetic PCL
SET:BLC
|
2.3B THB | 8.3 | 13.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
875.9B USD | 28.6 | 42.4 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
580.2B USD | 15 | 21.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.5B GBP | 17.2 | 31.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 11.6 | 19.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
299.1B USD | 10.1 | 16.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
236.4B CHF | 13.5 | 21.8 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 386.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 7.6 | 10.3 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
158.2B USD | 7.8 | 20.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.4B USD | 7.1 | 16.9 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 6.6 |
| Median | 8.6 |
| 70th Percentile | 11.4 |
| Max | 3 584.8 |
Other Multiples
Bangkok Lab and Cosmetic PCL
Glance View
Bangkok Lab & Cosmetic PCL engaes in the provision of pharmaceuticals and health products. The company is headquartered in Bangkok, Bangkok Metropolis. The company went IPO on 2023-06-21. The firm is engaged in the production of medicines and health products by selecting raw materials. The firm has produced more than 100 products. Its products include ZENZERA 200 SUSPENSION, ZENZERA, SYNOVAR UC40, RADIARA, PROCEMINE, FANGO-B, EMBLICOF COUGH MIXTURE, CLINIGEL STERILE, RAQUA FIBROTA, RAQUA COLLAGEN, SYNOVAR UC, SYNOVAR POWDER, NACOXIB, LUTI-BERRY MIXED, ZIGA GEL (orange), ZERTINE SYRUP, VIZO Cream, SPORAXYL CREAM, NORAPHEN, MURHINOL-250 SYRUP, NORFLOXYL 400, NOCID, MURHINOL-250 SYRUP, MUCOBROX, GYNOSTEN CREAM, and GYNOSTEN 500, AROTIKA COOL GEL, ALLERAX-FC, AROTIKA RUB LOTION (SPRAY), Calza c Dietary Supplement, Calza PLUS POWDER Dietary, and Calza-750 TAB FC, among others. Its products are distributed through Bangkok Drug Co., Ltd., Beereach (Thailand) Co., Ltd., Pharmaline Company Limited, Pharma Alliance Company Ltd., and Bangkok Medica Co., Ltd.
